Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nutritional modulation of disease severity in acute pancreatitis: metabolic pathways, inflammatory signaling, and diet-responsive clinical outcomes.

Frontiers in nutrition·2026
Same author

Subnanoscale IrW oxide anodes: breaking immiscibility for high activity and durability in water electrolysis.

Chemical communications (Cambridge, England)·2026
Same author

S-acylation switches the fate of a plant peptide precursor in cell wall damage responses.

Science advances·2026
Same author

Galangin Ameliorates Acetaminophen-Induced Acute Liver Injury by Inhibiting Ferroptosis through the Prevention of Chaperone-Mediated Autophagic Degradation of FTH1.

Journal of agricultural and food chemistry·2026
Same author

Urinary ANGPTL3: a novel noninvasive biomarker for podocyte injury in pediatric glomerular diseases.

Journal of translational medicine·2026
Same author

Using Pragmatic Co-Design Processes in a Resource-Constrained Regional Health Service: Insights From the TROPICAL-VIC Early Referral to Palliative Care Project.

The Australian journal of rural health·2026

Related Experiment Video

Updated: Feb 26, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

12.5K

Exploring potential biomarkers of diffuse large B-cell lymphoma through multi-dimensional data.

Chi Li1, Xinli Han1, Xiaoshuang Hu1

  • 1Department of Pediatric Hematology Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.

Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
|February 25, 2026
PubMed
Summary

This study identifies novel plasma protein biomarkers for diffuse large B-cell lymphoma (DLBCL). Six proteins show robust associations, with three (MTHFD1, PPIL1, WDR5) predicting poor prognosis, aiding DLBCL risk assessment and treatment.

Keywords:
BiomarkerDiffuse large B-cell lymphomaGeneticsMendelian randomizationPlasma protein

More Related Videos

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

8.1K
From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

14.3K

Related Experiment Videos

Last Updated: Feb 26, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

12.5K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

8.1K
From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

14.3K

Area of Science:

  • Genetics
  • Oncology
  • Biomarker Discovery

Background:

  • Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous cancer with unpredictable outcomes.
  • Effective risk stratification and targeted therapies require reliable biomarkers.

Purpose of the Study:

  • To systematically investigate the causal relationship between plasma proteins and DLBCL risk.
  • To identify and validate novel protein and transcriptional biomarkers for DLBCL prognosis.

Main Methods:

  • Utilized two-sample Mendelian randomization (MR) analysis on 4907 plasma proteins.
  • Integrated transcriptomic data and employed Bayesian co-localization and reverse MR analyses.
  • Validated prognostic significance of identified biomarkers in independent patient cohorts.

Main Results:

  • Identified 52 plasma proteins associated with DLBCL risk.
  • Six proteins (GOLM1, ISOC1, MTHFD1, PPIL1, RACGAP1, WDR5) showed robust protein and transcriptional relevance.
  • MTHFD1, PPIL1, and WDR5 were consistently linked to poor DLBCL prognosis.

Conclusions:

  • Discovered novel protein and transcriptional biomarkers for DLBCL.
  • These biomarkers offer potential for improved risk assessment and early prognosis prediction in DLBCL patients.